Analyst Tara Bancroft of TD Cowen maintained a Buy rating on TG Therapeutics, retaining the price target of $50.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tara Bancroft’s rating is based on several positive indicators for TG Therapeutics. The company reported a solid 10% quarter-over-quarter increase in net US Briumvi revenue for Q3, aligning with expectations and slightly surpassing consensus estimates. This growth is particularly noteworthy given the typical seasonal impacts on revenue during this period.
Additionally, the expansion of Briumvi’s availability into new international markets, including Kuwait and the UAE, through a collaboration with Neuraxapharm, suggests potential for further revenue growth. The company’s management highlighted strong new patient enrollments and repeat prescriptions, driven by Briumvi’s efficacy, safety, and convenience, which have been well-received by the medical community. These factors, combined with the company’s increased 2025 US net Briumvi revenue guidance, underpin Bancroft’s Buy rating.
Bancroft covers the Healthcare sector, focusing on stocks such as Urogen Pharma, Geron, and TG Therapeutics. According to TipRanks, Bancroft has an average return of 16.6% and a 48.45% success rate on recommended stocks.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $60.00 price target.